Atomic force microscopy studies of functional and dysfunctional pulmonary surfactant films, II: albumin-inhibited pulmonary surfactant films and the effect of SP-A.
Pulmonary surfactant (PS) dysfunction because of the leakage of serum proteins into the alveolar space could be an operative pathogenesis in acute respiratory distress syndrome. Albumin-inhibited PS is a commonly used in vitro model for studying surfactant abnormality in acute respiratory distress syndrome. However, the mechanism by which PS is inhibited by albumin remains controversial. This study investigated the film organization of albumin-inhibited bovine lipid extract surfactant (BLES) with and without surfactant protein A (SP-A), using atomic force microscopy. The BLES and albumin (1:4 w/w) were cospread at an air-water interface from aqueous media. Cospreading minimized the adsorption barrier for phospholipid vesicles imposed by preadsorbed albumin molecules, i.e., inhibition because of competitive adsorption. Atomic force microscopy revealed distinct variations in film organization, persisting up to 40 mN/m, compared with pure BLES monolayers. Fluorescence confocal microscopy confirmed that albumin remained within the liquid-expanded phase of the monolayer at surface pressures higher than the equilibrium surface pressure of albumin. The remaining albumin mixed with the BLES monolayer so as to increase film compressibility. Such an inhibitory effect could not be relieved by repeated compression-expansion cycles or by adding surfactant protein A. These experimental data indicate a new mechanism of surfactant inhibition by serum proteins, complementing the traditional competitive adsorption mechanism.
Zuo
Yi Y
YY
Department of Chemistry, University of Western Ontario, London, Ontario, Canada.
Tadayyon
Seyed M
SM
Keating
Eleonora
E
Zhao
Lin
L
Veldhuizen
Ruud A W
RA
Petersen
Nils O
NO
Amrein
Matthias W
MW
Possmayer
Fred
F
D000327:Adsorption; D000388:Air; D000818:Animals; D002417:Cattle; D006801:Humans; D008055:Lipids / Q000037:antagonists & inhibitors*; D018625:Microscopy, Atomic Force; D008856:Microscopy, Fluorescence; D010743:Phospholipids / Q000037:antagonists & inhibitors / Q000378:metabolism; D011312:Pressure; D037662:Pulmonary Surfactant-Associated Protein A / Q000494:pharmacology*; D011663:Pulmonary Surfactants / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000494:pharmacology* / Q000627:therapeutic use; D013499:Surface Properties; D014867:Water / Q000737:chemistry
D008055:Lipids; D010743:Phospholipids; D037662:Pulmonary Surfactant-Associated Protein A; D011663:Pulmonary Surfactants; D014867:Water; D012710:Serum Albumin, Bovine